{
    "_id": "34012000|None",
    "id": "34012000",
    "infons": {},
    "passages": [
        {
            "infons": {
                "journal": "Nat Rev Drug Discov. 2021 Jun;20(6):412-413. doi: 10.1038/d41573-021-00088-6.",
                "year": "2021",
                "type": "title",
                "authors": "Kingwell K"
            },
            "offset": 0,
            "text": "Double setback for ASO trials in Huntington disease.",
            "sentences": [],
            "annotations": [
                {
                    "id": "1",
                    "infons": {
                        "identifier": "MESH:D006816",
                        "type": "Disease",
                        "valid": true,
                        "normalized": [
                            "D006816"
                        ],
                        "database": "ncbi_mesh",
                        "normalized_id": "D006816",
                        "biotype": "disease",
                        "name": "Huntington Disease",
                        "accession": "@DISEASE_Huntington_Disease"
                    },
                    "text": "Huntington disease",
                    "locations": [
                        {
                            "offset": 33,
                            "length": 18
                        }
                    ]
                }
            ],
            "relations": []
        },
        {
            "infons": {
                "type": "abstract"
            },
            "offset": 53,
            "text": "",
            "sentences": [],
            "annotations": [],
            "relations": []
        }
    ],
    "relations": [],
    "pmid": 34012000,
    "pmcid": null,
    "meta": {},
    "date": "2021-06-01T00:00:00Z",
    "journal": "Nat Rev Drug Discov",
    "authors": [
        "Kingwell K"
    ],
    "relations_display": []
}